Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features

Journal of Clinical Oncology

Volumn 29, Issue 11, 2011, Pages 1415-1423

  Tamayo, Pablo ^a,b,c,d,e,f   Cho, Yoon Jae ^a,b,c,d,e,f   Tsherniak, Aviad ^a,b,c,d,e,f   Greulich, Heidi ^a,b,c,d,e,f   Ambrogio, Lauren ^a,b,c,d,e,f   Meeteren, Netteke Schouten Van ^a,b,c,d,e,f   Zhou, Tianni ^a,b,c,d,e,f   Buxton, Allen ^a,b,c,d,e,f   Kool, Marcel ^a,b,c,d,e,f   Meyerson, Matthew ^a,b,c,d,e,f   Pomeroy, Scott L ^a,b,c,d,e,f   Mesirov, Jill P ^{a,b,c,d,e,f,g}  

^a HARVARD UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f CHILDREN S ONCOLOGY GROUP   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; COPY NUMBER VARIATION; FALSE POSITIVE RESULT; GENE EXPRESSION; GENETIC DISORDER; GENETIC RISK; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MEDULLOBLASTOMA; METASTASIS; ONCOGENE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CLASSIFICATION;

BAYES THEOREM; CEREBELLAR NEOPLASMS; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE;

EID: 79953146403     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.1675     Document Type: Article

References (52)

1. Cho YJ, Pomeroy SL: Targeted therapy in medulloblastoma, in Houghton PJ, Arceci R (eds): Molecularly Target Therapy for Childhood Cancer. New York, NY, Springer Verlag, 2009, pp 350
2. Packer RJ, Goldwein J, Nicholson HS, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17:2127-2136, 1999 (Pubitemid 29318845)
3. Albright AL, Wisoff JH, Zeltzer PM, et al: Effects of medulloblastoma resections on outcome in children: A report from the Children's Cancer Group. Neurosurgery 38:265-271, 1996 (Pubitemid 26030705)
4. Thomas PR, Deutsch M, Kepner JL, et al: Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18:3004-3011, 2000 (Pubitemid 30644125)
5. Bailey CC, Gnekow A, Wellek S, et al: Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma: International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO)-SIOP II. Med Pediatr Oncol 25:166-178, 1995
6. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442, 2002 (Pubitemid 34100955)
7. Crawford JR, MacDonald TJ, Packer RJ: Medulloblastoma in childhood: New biological advances. Lancet Neurol 6:1073-1085, 2007 (Pubitemid 350116703)
8. Giangaspero R, Perry R, Kelly P, et al: Tumours of the central nervous system, in Kleihues P, Cavenee W (eds): World Health Organization Classification of Tumours: Pathology and Genetics- Tumours of the Nervous System. Lyon, France, IARC Press, 2000
9. Eberhart CG, Kepner JL, Goldthwaite PT, et al: Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 94:552-560, 2002 (Pubitemid 34081387)
10. Gilbertson R, Wickramasinghe C, Hernan R, et al: Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85:705-712, 2001 (Pubitemid 32929469)
11. Rutkowski S, von Bueren A, von Hoff K, et al: Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: Results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13:2651-2657, 2007 (Pubitemid 46788032)
12. Lamont JM, McManamy CS, Pearson AD, et al: Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482-5493, 2004 (Pubitemid 39100486)
13. de Haas T, Hasselt N, Troost D, et al: Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res 14:4154-4160, 2008
14. Pfister S, Remke M, Benner A, et al: Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27:1627-1636, 2009
15. Mendrzyk F, Radlwimmer B, Joos S, et al: Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 23:8853-8862, 2005 (Pubitemid 46211532)
16. Haberler C, Slavc I, Czech T, et al: Histopathological prognostic factors in medulloblastoma: High expression of survivin is related to unfavourable outcome. Eur J Cancer 42:2996-3003, 2006 (Pubitemid 44755258)
17. Thompson MC, Fuller C, Hogg TL, et al: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924-1931, 2006 (Pubitemid 46638992)
18. Fattet S, Haberler C, Legoix P, et al: Betacatenin status in paediatric medulloblastomas: Correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 218:86-94, 2009
19. Segal RA, Goumnerova LC, Kwon YK, et al: Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 91:12867-12871, 1994
20. Mootha VK, Lindgren CM, Eriksson KF, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273, 2003 (Pubitemid 36792858)
21. Subramanian A, Tamayo P, Mootha VK, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-15550, 2005 (Pubitemid 41528093)
22. Barbie DA, Tamayo P, Boehm JS, et al: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112, 2009
23. Wolfer A, Wittner BS, Irimia D, et al: MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A 107:3698-3703, 2010
24. Bild AH, Yao G, Chang JT, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357, 2006 (Pubitemid 43128862)
25. Edelman E, Porrello A, Guinney J, et al: Analysis of sample set enrichment scores: Assaying the enrichment of sets of genes for individual samples in genome-wide expression profiles. Bioinformatics 22:e108-e116, 2006 (Pubitemid 44307811)
26. Lee E, Chuang HY, Kim JW, et al: Inferring pathway activity toward precise disease classification. PLoS Comput Biol 4:e1000217, 2008
27. Burnside ES, Rubin DL, Fine JP, et al: Bayesian network to predict breast cancer risk of mammographic microcalcifications and reduce number of benign biopsy results: Initial experience. Radiology 240:666-673, 2006 (Pubitemid 44267321)
28. Gevaert O, De Smet F, Timmerman D, et al: Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks. Bioinformatics 22:e184-e190, 2006 (Pubitemid 44288285)
29. Nagl S, Williams M, Williamson J: Objective Bayesian nets for systems modelling and prognosis in breast cancer, in Holmes DE, Jain LC (eds): Innovations in Bayesian Networks: Theories and Applications. Berlin, Germany, Springer, 2008, pp 131-167
30. Sebastiani P, Nolan VG, Baldwin CT, et al: A network model to predict the risk of death in sickle cell disease. Blood 110:2727-2735, 2007 (Pubitemid 47523196)
31. Swartz RJ, West LA, Boiko I, et al: Classification using the cumulative log-odds in the quantitative pathologic diagnosis of adenocarcinoma of the cervix. Gynecol Oncol 99:S24-S31, 2005 (suppl 1) (Pubitemid 41774304)
32. Možina M, Demšar J, Kattan M, et al: Nomograms for visualization of naive Bayesian classifier. Presented at the 8th European Conference on Principles and Practice of Knowledge Discovery in Databases, Pisa, Italy, September 20-24, 2004
33. Kool M, Koster J, Bunt J, et al: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3:e3088, 2008
34. Yu D, Cozma D, Park A, et al: Functional validation of genes implicated in lymphomagenesis: An in vivo selection assay using a Myc-induced B-cell tumor. Ann N Y Acad Sci 1059:145-159, 2005 (Pubitemid 43211617)
35. Majumder PK, Febbo PG, Bikoff R, et al: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594-601, 2004 (Pubitemid 38796850)
36. Högerkorp CM, Bilke S, Breslin T, et al: CD44- stimulated human B cells express transcripts specifically involved in immunomodulation and inflammation as analyzed by DNA microarrays. Blood 101:2307-2313, 2003 (Pubitemid 36302074)
37. Coller HA, Grandori C, Tamayo P, et al: Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 97:3260-3265, 2000 (Pubitemid 30183289)
38. Kegg: Histidine metabolism: Reference pathway. http://www.genome.jp/kegg/ pathway/map/map00340 html
39. Yoon JW, Kita Y, Frank DJ, et al: Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 277:5548-5555, 2002 (Pubitemid 34968606)
40. Zhang Y, Jamaluddin M, Wang S, et al: Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 77:5933-5947, 2003 (Pubitemid 36538985)
41. Cho J-Y, Tsherniak A, Tamayo P, et al: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29:1424-1430, 2011
42. Herms J, Neidt I, Lüscher B, et al: C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89:395-402, 2000
43. Beroukhim R, Getz G, Nghiemphu L, et al: Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci U S A 104:20007-20012, 2007
44. Baker SG, Cook NR, Vickers A, et al: Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc 172:729-748, 2009
45. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44:837-845, 1988
46. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27:157-172, 2008; discussion 207-212 (Pubitemid 351193639)
47. Salvesen HB, Carter SL, Mannelqvist M, et al: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 106:4834-4839, 2009
48. Dickson BC, Mulligan AM, Zhang H, et al: High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20:685-693, 2007 (Pubitemid 46788875)
49. Harrell FE: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer- Verlag, 2001
50. Iasonos A, Schrag D, Raj GV, et al: How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26:1364-1370, 2008
51. Cronin M, Sangli C, Liu ML, et al: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53: 1084-1091, 2007 (Pubitemid 46867525)
52. Slodkowska EA, Ross JS: MammaPrint 70- gene signature: Another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 9:417-422, 2009